Metrics are critical to efforts for reining in clinical trials that are either poorly initiated or have incurred unforeseen events which place the original timelines and/or budgets at risk of overages. They also drive competitive performance among those organizations performing trials.
The focus on technology as a driver of performance improvement in clinical trials in intense, but despite years of valiant efforts, study execution remains far from optimal. For study startup, the data are dismal.
Where are the bottlenecks in starting clinical trials? It’s an obvious question to ask, but unfortunately, the tools traditionally used to conduct clinical trials lack robust reporting capabilities. Today, BI initiatives continue to top sponsor and CRO priorities, as executives demand greater visibility into trial data at a much faster pace.
The clinical trials sector is heavily invested in technologies that track how studies unfold. But, putting that information to good use requires turning real-time visibility into actionable data. Until recently, use of BI in clinical trials has been far from commonplace. But that is beginning to change, driven largely by a need to revamp how studies are conducted in today’s ultra-competitive global marketplace.
For years, the laborious step of standardization has ranked as the lengthiest of clinical trial study startup activities, and recent data suggest it remains the primary cause of site activation failure. Breaking down key benchmarks into their component sub-steps provides more accurate identification of where these bottlenecks may occur. Measuring sub-steps enables building predictive models which can condense contract cycle times and optimize trial operations. Learn more at...
Seventy-two percent of clinical studies run more than one month behind schedule due to poor management of trial issues. Learn how to identify the red flags that signal a study is veering off course and how to avoid them.